Abstract
The β-lactam β-lactamase inhibitor combinations (ampicillin/clavulanate, ampicillin/sulbactam, ticarcillin/clavulanate and piperacillin/tazobactam) were tested against selected inhibitor-resistant class A β-lactamases of the TEM and OHIO-1 varieties. Minimum inhibitor concentrations (MIC) revealed that the Escherichia coli DH5α transconjugate strains that possessed the OHIO-1 β-lactamase, Met 69Ile mutant of the OHIO-1 β-lactamase, TEM-30 (Arg 244Ser) and TEM-31 (Arg 244Cys) β-lactamase were most susceptible to piperacillin and piperacillin/tazobactam. Kinetic experiments with each β-lactamase demonstrated that tazobactam was 10-25-fold more potent than clavulanate or sulbactam against TEM-30 and TEM-31 β-lactamase. Tazobactam was also as effective as clavulanate against the Met 69Ile mutant of the OHIO-1 β-lactamase. Among the clinically available β-lactams and β-lactamase inhibitors, piperacillin/tazobactam appears to be the most potent combination against selected inhibitor-resistant strains of TEM and OHIO-1 β-lactamase.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
